Cross-Sector entity

Tandem Diabetes Care

Company
6

Every one of those 2 sits in a single category, ipo. Tandem Diabetes Care is most often covered alongside Medtronic Plc, which appears in 2 of these 2 stories. We currently track 2 Cross-Sector stories that mention Tandem Diabetes Care, all published on March 6, 2026.

2 verified stories tracked

Last mentioned: Mar 6, 2026

Entity pulse

Recent coverage · Tandem Diabetes Care

2 stories
6 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Tandem Diabetes Care

Every one of those 2 sits in a single category, ipo. Tandem Diabetes Care is most often covered alongside Medtronic Plc, which appears in 2 of these 2 stories. We currently track 2 Cross-Sector stories that mention Tandem Diabetes Care, all published on March 6, 2026. Each carries 2 original sources on average.

Stories tracked
2
Sources per story
2

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Tandem Diabetes Care. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. IPO Pricing

    MiniMed prices 28 million shares at $20.00 per share, raising $560 million.

  2. Analyst Debate

    Market analysts debate the valuation of the diabetes unit amid competitive pressures.

  3. Initial Filing

    Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.

Stories mentioning Tandem Diabetes Care 2

Finance ipo Neutral 6

Medtronic’s MiniMed Prices $560 Million IPO at $20 Per Share

Medtronic plc has priced the initial public offering of its diabetes-focused subsidiary, MiniMed Group Inc., at $20.00 per share for 28 million shares. The $560 million carve-out aims to provide the specialized unit with independent capital to compete in the high-growth insulin delivery and monitoring market.

2 sources